CD19 Targets New Fc Optimized Immune Enhancement Monoantid Tafasitamab To Apply for Listing in the U.S.
-
Last Update: 2020-06-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, MorphoSys announced that it had filed a patentasitamab (MOR208) biologics licensing application (BLA) with the U.SFood and Drug Administration (FDA) to treat patients with recurrent or refractive diffuse large B-cell lymphoma (r/r DLBCL)Tafasitamab is a new type of human-derived Fc domain optimized immune-enhanced monoclonal antibody, CD19 is a clear biomarker of a variety of B-cell malignanciesfda has a 60-day filing review period to determine whether the BLA is complete and acceptedDr Malte Peters, Chief Development Officer of MorphoSys, said: "This BLA submission marks an important milestone in MorphoSys' history and demonstrates our commitment to addressing the high medical needs of recurrent or refractive DLBCLIf approved, the tafasitamab-to-nadoamine programme will be an alternative treatment option for the group of patients with this serious disease"
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
